Blue Eyes Intelligence Engineering and Sciences Publication (BEIESP)
Ahan Gadkari
Sofia Dash
2022-01-30
<p>The availability of vaccinations against COVID-19 provides hope for containing the epidemic, which has already claimed over 2.84 million lives. However, inoculating millions of individuals worldwide would need large vaccine manufacturing followed by fair distribution. A barrier to vaccine development and dissemination is the developers' intellectual property rights. India and South Africa have jointly sought to the World Trade Organization that certain TRIPS rules of COVID-19 vaccines, medicines, and treatments be waived. This piece argues for such a waiver, highlighting the unique circumstances that exist. It believes that TRIPS's flexibilities are inadequate to cope with the present epidemic, particularly for nations without pharmaceutical manufacturing competence.</p>
https://doi.org/10.35940/ijrte.E6675.011052
oai:zenodo.org:5804101
eng
Zenodo
issn:2277-3878
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
International Journal of Recent Technology and Engineering (IJRTE), 10(5), 61-65, (2022-01-30)
Intellectual Property Rights, COVID-19 Vaccines, TRIPS Agreement, WTO
Not Tripping over TRIPS: An Analysis of Necessity and Legality of the COVID-19 TRIPS Waiver Proposal
info:eu-repo/semantics/article